Spurned By NICE On Avastin In Bowel Cancer, Roche Looks To U.K. Cancer Drugs Fund
This article was originally published in The Pink Sheet Daily
NICE's definitive decision against Avastin in bowel cancer forces Roche to turn to Cancer Drugs Fund.
You may also be interested in...
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.
Agency officials stress that FDA is eager to work with Genentech on future studies to identify a subpopulation of responders.
NICE rejection of Roche's Avastin comes a week ahead of target dates for U.S. and EU decisions on possibly withdrawing the indication, but still offers instructive lessons for working with technology assessment groups.